Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.37 |
| ▸ | BMI1 | P35226 | 3/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18100964 | 0.90 | BMI1 (0.36) | AGPAT2DHODHBMI1MCHR1ABCB1 | |
| SCHEMBL16739922 | 0.89 | AGPAT2 (0.35) | AGPAT2DHODHBMI1SYKGPR139 | |
| SCHEMBL16747876 | 0.87 | AGPAT2 (0.41) | AGPAT2DHODHBMI1ABCB1SYK | |
| SCHEMBL16747966 | 0.85 | CSNK1D (0.40) | AGPAT2DHODHBMI1ABCB1SYK | |
| SCHEMBL18100965 | 0.83 | KMT2A (0.39) | AGPAT2DHODHABCB1POLB | |
| SCHEMBL16747837 | 0.83 | KCNH2 (0.42) | AGPAT2DHODHBMI1MCHR1CYP11B1 | |
| SCHEMBL16747881 | 0.80 | MCHR1 (0.33) | AGPAT2DHODHBMI1MCHR1SYK | |
| SCHEMBL16540578 | 0.79 | BMI1 (0.39) | AGPAT2BMI1 | |
| SCHEMBL15741400 | 0.79 | AGPAT2 (0.39) | AGPAT2DHODHBMI1MCHR1ABCB1 | |
| SCHEMBL18103453 | 0.79 | FADS1 (0.32) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | AGPAT2 4306/4885DHODH 3196/4885BMI1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.